Corrigendum to "Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation" [Contemp. Clin. Trials Commun. 33 (2023) 101144]

Contemp Clin Trials Commun. 2024 Apr 27:39:101302. doi: 10.1016/j.conctc.2024.101302. eCollection 2024 Jun.

¹ Children's National Hospital, Division of Gastroenterology, Hepatology and Nutrition, Washington, DC, USA.
² Takeda Development Center Americas, Inc., Lexington, MA, USA.
³ Takeda Development Center Americas, Inc., Zurich, Switzerland.

Abstract

[This corrects the article DOI: 10.1016/j.conctc.2023.101144.].